Posted by Michael Wonder on 22 Feb 2017
We price drugs in line with innovation potential, says Bayer CEO
22 February 2017 - When it comes to drug pricing and the political rhetoric coming out from the U.S. administration, the chief executive of pharmaceutical firm Bayer told CNBC that it prices products in relation to the environment and each ones capability.
"We price our drugs in line with their innovation potential and in line with the competitive environment," Werner Baumann, CEO of Bayer, told CNBC on Wednesday.
Shortly after Donald Trump was sworn in as the 45th U.S. President, he met with pharmaceutical executives to discuss drug manufacturing and pricing.
